You are looking at 161 - 170 of 4,557 items for

  • Refine by Access: Content accessible to Me x
Clear All
Full access

HSR24-152: Patient-Reported Outcome (PRO) Data in Oncology NDAs Approved by the FDA (2018–2021): A Review of Criticism and Concerns in Comments From Regulators

Erin Comerford, Lindsey Norcross, Medha Sasane, Ying Zheng, and Ari Gnanasakthy

Full access

HSR24-153: Real-World Clinical Outcomes of First-Line Therapies and Treatment Regimens for BRAF-Mutant Advanced/Metastatic Melanoma: Retrospective Observational Study

Ruixuan Jiang, Geoffrey Johnson, Emilie Scherrer, John Kang, Kathleen M. Aguilar, Rohini Singh, and Eric D. Whitman

Full access

HSR24-154: Real-World Clinical Outcomes in Patients With Advanced/Metastatic Melanoma and Brain Metastases Treated With Pembrolizumab Monotherapy—An Analysis of the ADOReg German Skin Cancer Registry

Ruixuan Jiang, Michael Weichenthal, Cesar I. Fernandez-Lazaro, Anja Rudolph, Clemens Krepler, Peter Mohr, and on behalf of the ADOReg investigators

Full access

HSR24-155: Disparities in Real-World Screening Mammography Compliance Rates by Body Mass Index and Mobility-Restricting Diagnosis—A Commercial Claims-Based Analysis

Julia Olsen, Scott Pohlman, and Jason Shames

Full access

HSR24-156: Treatment Patterns and Blood Count Control in 10,112 Patients With Polycythemia Vera Managed at Community Practices in the United States

Jingbo Yu, Anupama Vasudevan, Harvey Katzen, and Evan Braunstein

Full access

HSR24-157: Standalone Performance Evaluation of an Artificial Intelligence Breast Cancer Detection Tool on Consecutively Collected Biopsy Proven Breast Cancer and Screening Negative Tomosynthesis Cases

Liyang Wei, Ashwini Kshirsagar, Julia Olsen, and Chirag Parghi

Full access

HSR24-158: Working and Cancer: The Impact of Cancer Diagnosis and Treatment on Employment, Presenteeism, and Productivity

Anuraag R. Kansal, Sarah A. Cohn, Shelley Fuld Nasso, Elena M. Jeannotte, and Haley V. Smoot

Full access

HSR24-159: Relationship Between Durable Transfusion Independence (TI) and Survival Outcomes in Patients (Pts) With Lower-Risk Myelodysplastic Syndrome (LR-MDS): An Analysis From US Health Insurance Claims Data

Rami S. Komrokji, Nishan Sengupta, Dylan Supina, Shyamala Navada, Ravi Potluri, Rohit Tyagi, Timothy Werwath, Zhouer Xie, Eric Padron, and David Sallman

Full access

HSR24-160: Immune Checkpoint Inhibitor-Induced Type 1 Diabetes Mellitus: Patient Characteristics, Clinical Outcomes, and Survival Implications of Autoantibodies

John Sharp, Cassandra Pasadyn, Songzhu Zhao, Lai Wei, Carolyn Presley, Dwight Owen, Kathleen Wyne, and Alexa Meara

Full access

HSR24-161: Biomarker Testing, Surgical Outcomes, and Adjuvant Therapy Rates Among Patients With Resected Non–Small Cell Lung Cancer (NSCLC) in the Community Setting in the United States (US), 2019–2023

Xiaohan Hu, Yu-Han Kao, Ashwini Arunachalam, Diana Chirovsky, Yiru Wang, Chenan Zhang, Kaitlyn Kane, and Ayman Samkari